Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Steinacker, Petraa | Klafki, Hansb | Lehnert, Stefana | Jesse, Saraha | v. Arnim, Christine A.F.a | Tumani, Hayrettina | Pabst, Alicea | Kretzschmar, Hans A.c | Wiltfang, Jensb | Otto, Markusa; *
Affiliations: [a] Department of Neurology, University of Ulm, Ulm, Germany | [b] Department of Psychiatry, University of Essen-Duisburg, Essen, Germany | [c] Institute of Neuropathology, LMU Munich, Munich, Germany
Correspondence: [*] Correspondence to: Markus Otto, MD, Department of Neurology, University of Ulm, Steinhövelstr. 1, 89075 Ulm, Germany. Tel.: +49 731 500 63010; Fax: +49 731 500 63012; E-mail: markus.otto@uni-ulm.de.
Abstract: The clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by several biochemical markers in cerebrospinal fluid (CSF) such as 14-3-3 proteins and tau protein. Unfortunately, none of the currently known markers are suited for screening or seems to be directly related to the pathophysiological process. A marker fulfilling these criteria might facilitate the early detection and might also serve in monitoring drug efficacy. Recently, the extracellular signal-regulated kinase ERK1/2 was detected in CSF of patients with neuropsychiatric disorders. Furthermore, ERK1/2 was reported to be activated in brains of animals infected with pathological prion protein. Therefore, we investigated CSF of 19 patients with CJD, 23 patients with other dementias including patients with Alzheimer's disease, and 12 patients with other neurological disorders. The measurement of ERK1/2 in the CSF samples was performed with an electrochemiluminescence assay and Western immunoblot. ERK1/2 and doubly phosphorylated ERK1/2 (pERK1/2) were detected in all patient groups. Significantly elevated mean levels of total ERK1/2 and pERK1/2 were found in the CJD patients. This increase was also observed in a CJD case that was negative for 14-3-3 protein or in CJD cases that had low levels of tau protein. Western immunoblot analysis suggested that ERK2 was the predominant form of ERKs present in our CSF samples. This pilot study suggests that ERK1/2 is a potential CSF biomarker for CJD, directly associated with the pathophysiological processes. Analysis of larger sample cohorts including other diseases with rapid neurodegeneration are required to confirm our findings.
Keywords: Alzheimer's disease, biomarker, cerebrospinal fluid, Creutzfeldt-Jakob disease, duplex electrochemiluminescence assay, extracellular signal-regulated kinase ERK1/2
DOI: 10.3233/JAD-2010-100030
Journal: Journal of Alzheimer's Disease, vol. 22, no. 1, pp. 119-128, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl